Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension
about
sameAs
Nitric oxide and cardiovascular effects: new insights in the role of nitric oxide for the management of osteoarthritisThe Role of Oxygen Sensors, Hydroxylases, and HIF in Cardiac Function and DiseaseThe safety of rofecoxibEffects of low-dose aspirin on blood pressure and endothelial function of treated hypertensive hypercholesterolaemic subjectsClinical methods for the evaluation of endothelial function-- a focus on resistance arteries.Redundant vasodilator pathways underlying radial artery flow-mediated dilation are preserved in healthy aging.Globotriaosylsphingosine accumulation and not alpha-galactosidase-A deficiency causes endothelial dysfunction in Fabry disease.Cyclo-oxygenase-2 inhibition and endothelium-dependent vasodilation in younger vs. older healthy adults.The endothelium: influencing vascular smooth muscle in many ways.Endothelium-mediated control of vascular tone: COX-1 and COX-2 products.Deletion of Protein Tyrosine Phosphatase 1B (PTP1B) Enhances Endothelial Cyclooxygenase 2 Expression and Protects Mice from Type 1 Diabetes-Induced Endothelial DysfunctionSex differences in salt sensitivity to nitric oxide dependent vasodilation in healthy young adultsIn Silico Analysis of the Potential of the Active Compounds Fucoidan and Alginate Derived from Sargassum Sp. as Inhibitors of COX-1 and COX-2EDHF: an update.Adiponectin and hypertension.Effects of nitric oxide synthase inhibition with or without cyclooxygenase-2 inhibition on resting haemodynamics and responses to exendin-4.Endothelium-dependent vasodilatation in forearm is impaired in stroke patients.
P2860
Q21195404-BB70DAEE-5CFA-4A1E-A929-208954DF262DQ26780548-BB85330C-AD1C-4864-B829-D2F5988E36C7Q28176535-C9B0E656-3198-4AC1-A01B-35264B1DA71CQ28184682-9158667C-38E3-40C6-80B5-2D047137A5CCQ33242082-41DE3CAF-97DB-4189-A79F-264B282BEA84Q33747531-385CDA74-6C93-4F20-B761-0BED5125A4C0Q34257466-D0F65820-D9AE-4B53-BF60-B44D48D1F89EQ34554429-83333D86-2F29-49D0-84C9-F1E612C72D82Q34638538-FE1EA6BB-2D9E-4F5A-91C9-8CA965A310A6Q35376020-0E29AD13-7A9E-494D-99D9-43858FF8A130Q35606400-559BE851-97A3-4FAA-BCA4-358B1BA0D199Q35850567-0F4A9ACB-99B1-4391-BA7F-9B0106FDE106Q36122973-B5C3A6B9-0FCE-4865-A3AF-4ABE36D9B3EFQ37551123-7593D71B-CC83-4E1D-A2BE-58D08BA2E915Q37798714-AC98F3EA-C907-4500-990A-F3DFD3D0606DQ41603681-CF1B5060-6831-4257-BEAC-8CBE6C2EF782Q50773075-9021490F-976D-4AB0-89AD-2F7ECBF533A1
P2860
Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension
description
2003 nî lūn-bûn
@nan
2003 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Selective cyclo-oxygenase-2 in ...... ts with essential hypertension
@ast
Selective cyclo-oxygenase-2 in ...... ts with essential hypertension
@en
Selective cyclo-oxygenase-2 in ...... ts with essential hypertension
@nl
type
label
Selective cyclo-oxygenase-2 in ...... ts with essential hypertension
@ast
Selective cyclo-oxygenase-2 in ...... ts with essential hypertension
@en
Selective cyclo-oxygenase-2 in ...... ts with essential hypertension
@nl
prefLabel
Selective cyclo-oxygenase-2 in ...... ts with essential hypertension
@ast
Selective cyclo-oxygenase-2 in ...... ts with essential hypertension
@en
Selective cyclo-oxygenase-2 in ...... ts with essential hypertension
@nl
P2093
P921
P3181
P1476
Selective cyclo-oxygenase-2 in ...... ts with essential hypertension
@en
P2093
Andreas Mügge
Christoph Hanefeld
Daniel Bulut
Rouven Koll
Sina Liaghat
Thomas Miebach
P304
P3181
P356
10.1097/00004872-200309000-00015
P407
P577
2003-09-01T00:00:00Z